This is a news story, published by Science News, that relates primarily to Amtagvi news.
For more Amtagvi news, you can click here:
more Amtagvi newsFor more biology news, you can click here:
more biology newsFor more news from Science News, you can click here:
more news from Science NewsOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best science news, business news, entertainment news, and much more. If you like biology news, you might also like this article about
cancer immunotherapy. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest immune system news, immune cells news, biology news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
cell therapyScience News
•
68% Informative
Earlier this year , the FDA approved the first T cell therapy for a solid tumor, sold under the name Amtagvi .
To treat advanced melanoma, doctors remove tumor-infiltrating lymphocytes, a type of T cell known as TILs, from a patient’s own tumor and grow them in the lab.
VR Score
73
Informative language
75
Neutral language
51
Article tone
formal
Language
English
Language complexity
50
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links